English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 9 June 2020, 11:00 HKT/SGT

Source: Joonghun Pharmaceutical Co., Ltd.
Joonghun Pharmaceutical of Korea Targets Overseas Markets for Coronavirus Diagnostic Kits

SEOUL, KOREA, June 9, 2020 - (ACN Newswire) - With the worldwide spread of the Novel Coronavirus (COVID-19), orders for Korean diagnostic kits continue to roll in. As part of the effort to combat COVID-19, Joonghun Pharmaceutical announced that it was accelerating efforts to provide its JD COVID-19 qRT-PCR Kit for in vitro diagnostics internationally.

The JD COVID-19 qRT-PCR Kit uses Real-time RT-PCR (Real-time Reverse Transcription-Polymerase Chain Reaction), currently the main testing method for detecting SARS-CoV-2 virus in COVID-19, because of its excellent sensitivity and specificity.

Joonghun Pharmaceutical's diagnostic qRT-PCR Kit targets a single gene (N gene) of the coronavirus, based on the FDA and CDC response to COVID-19. Targeting the single gene accords with FDA Test Validation FAQs which note recent evidence suggesting appropriately validated single gene detection (single viral target SARS-CoV-2 assay) provides acceptable performance. Joonghun's targeting the N gene is based on the US CDC diagnostic kit 'CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel' which targets N genes as well.

According to Joonghun Pharmaceutical, "We successfully conducted clinical trials using U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) clinical guidelines, in cooperation with university research institutes and government agencies." Furthermore, "Based on these clinical results, on April 17 we obtained an export license from the Korean Ministry of Food and Drug Safety, and received a European in vitro diagnostic (CE-IVD) certification, providing us with a foothold for meeting various needs around the world."

Joonghun Pharmaceutical is currently attending results of its FDA EUA application, submitted May 4th, 2020. The FDA approval process is expected to proceed smoothly as the product was verified in clinical trials. A spokesperson for Joonghun Pharmaceutical said requests for the supply of diagnostic kits are constantly coming from South America, Europe and parts of Asia where COVID-19 is still spreading, and obtaining EUA approval would provide another source of validation for these markets.

The company also produces the Joonghun Ribavirin capsule, one of 35 medicines recognized by the Korea Health Insurance Review and Assessment Service as a COVID-19 treatment. "Inquiries regarding Joonghun Ribavirin capsules surged from public institutions and distributors in countries across Europe and South America, and in March, at the request of Luxembourg, a total of 42,000 capsules were urgently exported."

"In order to contribute and help stabilize the global impact of COVID-19, we will increase the production of medicines, in order to respond quickly to urgent requests from domestic and international entities. Joonghun's JD COVID-19 qRT-PCR Kit is produced in a GMP facility for pharmaceuticals and medical devices, so we will be able to provide a stable supply." Joonghun Pharmaceutical also added, "In order to actively respond to the worldwide demand for diagnostic kits, we are also planning to release a rapid test kit in June."

Media contact
Joonghun Pharmaceutical Co., Ltd.
T: +82-2-2138-8114
E: [email protected]
U: www.joonghun.com

Topic: Press release summary
Sectors: BioTech, HealthCare
From the Asia Corporate News Network

Copyright © 2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


Latest Press Releases
ConnecTechAsia to Showcase Best-In-Class Virtual Experience  
Aug 14, 2020 10:42 HKT/SGT
Trintech Enhances Its Enterprise System of Accounting Intelligence with Release of Cadency 9.0  
Aug 14, 2020 00:00 HKT/SGT
Hi Sun Tech Announces 2020 Interim Results: Continues to Advance "Digitalization" Strategy  
Aug 13, 2020 22:20 HKT/SGT
ConnecTechAsia Reveals Details of Event to Deliver Best-In-Class Virtual Experience  
Aug 13, 2020 17:48 HKT/SGT
QBiotics Announces Clinical Collaboration with MSD Targeting Unresectable Melanoma  
Aug 13, 2020 15:30 HKT/SGT
ConnecTechAsia Reveals Details of Event to Deliver Best-In-Class Virtual Experience  
Aug 13, 2020 15:24 HKT/SGT
Mitsubishi Corporation Releases Financial Results for the Three Months Ended June 2020   
Aug 13, 2020 14:33 HKT/SGT
Huijing Holdings Limited Announces Positive Profit Alert for 2020 Interim  
Aug 13, 2020 14:00 HKT/SGT
PJSCB Orient Finans to start accepting JCB across the Republic of Uzbekistan  
Aug 13, 2020 11:00 HKT/SGT
NEC and PERSOL CAREER Start PoC of Recruitment Service for International IT Engineers using Blockchain Technology  
Aug 13, 2020 08:57 HKT/SGT
More Press release >>
More events >>
Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8575